{"entity":{"id":"zamtocabtagene-autoleucel","kind":"drug","name":"Zamtocabtagene autoleucel","aka":["zamtocabtagene autoleucel (MB-CART2019.1)"],"tldr":"Zamtocabtagene autoleucel is an experimental CAR-T cell therapy from Miltenyi Biomedicine in phase 2 trials for diffuse large B-cell lymphoma, primary CNS lymphoma and mantle cell lymphoma, aimed at CD19 and CD20.","summary":"Zamtocabtagene autoleucel (CART2019) is a CAR-T cell therapy developed by Miltenyi Biomedicine. Its targets are CD19 and CD20 (the sponsor names CD19-CD20). The sponsor states: tandem CAR-T approach targeting two B-cell antigens. ClinicalTrials.gov describes the intervention as: Tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in diffuse large B-cell lymphoma, primary CNS lymphoma and mantle cell lymphoma. The largest, NCT04792489, plans to enrol 315 participants with primary completion expected 2026-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Zamtocabtagene autoleucel","url":"https://clinicaltrials.gov/search?intr=CART2019"},{"label":"Sponsor page","url":"https://www.miltenyibiomedicine.com"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["dlbcl","primary-cns-lymphoma","mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":["cd19","cd20"],"drugs":[],"companies":["miltenyi-biomedicine"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04792489","nct07288879","nct04844866","nct06508931"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"CART2019","modality":"CAR-T cell therapy","mechanism":"tandem CAR-T approach targeting two B-cell antigens.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/zamtocabtagene-autoleucel/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"primary-cns-lymphoma","kind":"cancer","name":"Primary CNS lymphoma","route":"/cancers/primary-cns-lymphoma/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"company":[{"id":"miltenyi-biomedicine","kind":"company","name":"Miltenyi Biomedicine","route":"/companies/miltenyi-biomedicine/"}],"trial":[{"id":"nct07288879","kind":"trial","name":"DALY II Japan/MB-CART2019.1 for DLBCL","route":"/trials/nct07288879/"},{"id":"nct04792489","kind":"trial","name":"DALY II USA/ MB-CART2019.1 for DLBCL","route":"/trials/nct04792489/"},{"id":"nct04844866","kind":"trial","name":"Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients","route":"/trials/nct04844866/"},{"id":"nct06508931","kind":"trial","name":"Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms","route":"/trials/nct06508931/"}]}}